Cochrane · systematic review · CD008203
Statins for primary prevention of venous thromboembolism
Li, L, Zhang, P, Tian, JH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyStatin versus placebo for primary prevention of venous thromboembolism
Population: 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All cases of VTE Statin vs placebo | OR 0.57 [0.37, 0.86] | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Pulmonary embolism Statin vs placebo | no estimate extracted | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Deep vein thrombosis Statin vs placebo | no estimate extracted | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Any MI Statin vs placebo | OR 0.45 [0.3, 0.69] | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Any stroke Statin vs placebo | OR 0.51 [0.34, 0.78] | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Death Statin vs placebo | OR 0.8 [0.66, 0.96] | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Any serious adverse event Statin vs placebo | OR 1.07 [0.95, 1.2] | 1 study · 17802 participants | Moderate Downgraded: imprecision |
Rosuvastatin versus placebo for prevention of venous thromboembolism
Population: 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All cases of VTE Rosuvastatin vs placebo | OR 0.57 [0.37, 0.86] | 1 study · 17802 participants | Moderate |
Pulmonary embolism Rosuvastatin vs placebo | OR 0.77 [0.41, 1.46] | 1 study · 17802 participants | Moderate |
Deep vein thrombosis Rosuvastatin vs placebo | OR 0.45 [0.25, 0.79] | 1 study · 17802 participants | Moderate |
Any MI Rosuvastatin vs placebo | OR 0.45 [0.3, 0.69] | 1 study · 17802 participants | Moderate |
Any stroke Rosuvastatin vs placebo | OR 0.51 [0.34, 0.78] | 1 study · 17802 participants | Moderate |
Death after VTE Rosuvastatin vs placebo | OR 0.5 [0.2, 1.24] | 1 study · 17802 participants | Moderate |
Any serious adverse event Rosuvastatin vs placebo | OR 0.98 [0.9, 1.06] | 1 study · 17802 participants | High |